On October 22, 2020, Du, Wu; Wen, Kun; Fu, Yiwei; Lv, Haibin; He, Jinyun; Qin, Dekun; Li, Yu; Duan, Jingyi; Li, Yong; Ai, Chaowu; Tu, Zhilin; Chen, Yuanwei; Li, Xinghai published a patent.HPLC of Formula: 1211568-27-2 The title of the patent was A class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and application. And the patent contained the following:
The invention disclosed a class of bifunctional chimeric heterocyclic compounds for targeted degradation of androgen receptors and application. The claimed compound is shown in structure ARB-L-U (ARB = androgen receptor recognition/binding part; L = linker part; U = ubiquitin protease recognition/binding part). The claimed compound is prepared via multiple steps (procedure given). The prepared compound can perform targeted degradation on androgen receptors in prostate cancer cells, and suppress proliferation of the prostate cancer cells, and also show good metabolic stability and pharmacokinetic properties. The claimed compound has good application prospect in preparation of targeted chimeras for protein degradation of androgen receptors and in the preparation of drugs for treating related diseases regulated by the androgen receptors. The experimental process involved the reaction of tert-Butyl 4-(piperidin-4-ylmethyl)piperazine-1-carboxylate(cas: 1211568-27-2).HPLC of Formula: 1211568-27-2
The Article related to bifunctional chimeric heterocycle preparation androgen receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.HPLC of Formula: 1211568-27-2
Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics